EVGN

Evogene Ltd. EVGN

NasdaqSmall CapMaterials

13F Pro quality score

Rank #2,740 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$3.85M

Quarter to Dec 31

Net income

$-8.48M

Quarter to Dec 31

Free cash flow

$-13.64M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$75.0K total
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

EVGN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Evogene Ltd.'s annual filings on SEC EDGAR.

Evogene Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$3.9M$-8.5M—
FY 2024$5.6M$-16.5M—
FY 2023$3.0M$-23.9M—
FY 2022$1.7M$-26.6M—
FY 2021$930.0K$-27.8M—
FY 2020$1.0M$-23.4M—
Source: EVGN filings on SEC EDGAR →

EVGN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Evogene Ltd. (EVGN): stock profile, AI score and financials

Evogene Ltd. (EVGN) stock profile, AI quality score, and SEC EDGAR financial data, a Materials sector company. 13F Pro's AI-powered ranking engine scores EVGN at 20.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,740 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Evogene Ltd. reports quarterly revenue of $3.9M, net income of $-8.5M, free cash flow of $-13.6M. Top institutional holders of EVGN by reported 13-F value include SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS, XTX Topco Ltd, based on the most recent SEC filings. EVGN trades on the Nasdaq exchange and files with the SEC under CIK 1574565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evogene Ltd. directly from SEC EDGAR.

SEC EDGAR: CIK 1574565 →